Episodic Therapy for Genital Herpes in Sub-Saharan Africa: A Pooled Analysis from Three Randomized Controlled Trials
2011

Episodic Therapy for Genital Herpes in Sub-Saharan Africa

Sample size: 1478 publication 10 minutes Evidence: moderate

Author Information

Author(s): Helen A. Weiss, Gabriela Paz Bailey, Sam Phiri, Gerard Gresenguet, Jerome LeGoff, Jacques Pepin, David A. Lewis, Laurent Belec, Irving F. Hoffman, William C. Miller, Philippe Mayaud

Primary Institution: London School of Hygiene and Tropical Medicine

Hypothesis

Can the variation in impact of acyclovir on ulcer healing in trials across different African countries be explained by differences in the characteristics of the study populations?

Conclusion

Acyclovir may provide a slight benefit in healing genital ulcers, especially in HIV-1 co-infected patients.

Supporting Evidence

  • 63% of patients on acyclovir had healed ulcers compared to 57% on placebo.
  • 58% of participants were HIV-1 seropositive.
  • Small ulcers responded better to acyclovir treatment.

Takeaway

This study looked at how well acyclovir helps heal genital sores in people in Africa, finding it works a bit better for those with HIV.

Methodology

Pooled data from three randomized controlled trials were analyzed to estimate the impact of acyclovir on ulcer healing and lesional HIV-1 RNA.

Potential Biases

Potential biases related to participant selection and adherence to treatment were noted.

Limitations

The study could not evaluate the impact on healing within the first week due to the timing of follow-up visits.

Participant Demographics

The study included 1478 patients, with a median age of 28 years, and a majority were male (63%).

Statistical Information

P-Value

p=0.04

Confidence Interval

95% CI 0.98–1.18

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1371/journal.pone.0022601

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication